RT Book, Section
A1 Li, Howard
A1 Kern, Jeffrey A.
A2 Grippi, Michael A.
A2 Elias, Jack A.
A2 Fishman, Jay A.
A2 Kotloff, Robert M.
A2 Pack, Allan I.
A2 Senior, Robert M.
A2 Siegel, Mark D.
SR Print(0)
ID 1122366977
T1 Genetic and Molecular Changes in Lung Cancer: Prospects for a Personalized Pharmacological Approach to Treatment
T2 Fishman's Pulmonary Diseases and Disorders, 5e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-179672-9
LK accessmedicine.mhmedical.com/content.aspx?aid=1122366977
RD 2024/04/18
AB Lung  cancer  is  the  most  common  cause  of  cancer-related  death  in  men  and  women  worldwide,  responsible  for  over  1  million  deaths  annually.1  Each  year,  more  people  die  of  lung  cancer  than  of  the  next  three  leading  causes  of  cancer  death  combined:  breast,  colon,  and  prostate  cancer.  Despite  advances  in  surgical  techniques  and  combined  therapies,  lung  cancer  remains  a  disease  with  a  dismal  prognosis.  Although  1-year  survival  has  improved  over  the  past  few  decades,  overall  5-year  survival  has  remained  relatively  unchanged  at  12%  to  16%  over  the  past  30  years.2  These  data  underscore  the  need  to  develop  new  diagnostic  modalities  and  therapeutic  approaches  to  target  lung  cancer.